English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Limited data exists on the safety of probiotic supplementation in preterm infants with gastrointestinal (GI) surgical conditions. Aims: To assess the safety of Bifidobacterium breve (B. breve) M-16V supplementation in preterm in-fants with GI surgical conditions in our unit with regards to probiotic sepsis. Methods: This retrospective audit of prospectively collected data involved screening of neonatal data-bases to identify preterm infants. Results: Data on 33 preterm infants who underwent 43 GI surgeries and received probiotics was ana-lysed. The median (IQR) gestation at birth and postnatal age at surgery was 30 (26.8-30.7) weeks, and 5 (1-34) days respectively. Twelve (36.3%) infants received probiotics in the preoperative period, 24 (72.7%) received it in the post-operative period, and 10 (30.3%) received it both in the pre-operative and post-operative period. The median (IQR) post-operative age at commencement, duration and number of doses of probiotics was day 10 (6-13), 43 (34-56) days, and 70 (61-100) respectively. Only one infant died; the reason for death was midgut volvulus. None developed Bifidobacterial sepsis. Conclusions: Probiotic sepsis did not occur following B. breve M-16V supplementation in our small cohort of preterm infants with GI surgical conditions. Adequately powered randomised controlled trials are needed to confirm safety and efficacy of B. breve M-16V in this cohort.

Safety of Probiotic Supplementation in Preterm Infants with Gastrointestinal Surgical Conditions: A Retrospective Audit